Financial Data and Key Metrics Changes - Group sales increased by 6% for the quarter, core operating profit rose by 12%, and core earnings per share grew by 15% to 46.5p [3][4] - Cash generation remained strong with £3.7 billion generated in the first half, supporting further investments and shareholder returns [4][55] - The dividend for the quarter was 16p, and over £800 million of the share buyback program has been completed [4][55] Business Line Data and Key Metrics Changes - Specialty medicines sales grew by 15%, while vaccine sales increased by 9% in the quarter [3][33] - The oncology portfolio saw a significant increase of 42%, with Gempelli for endometrial cancer up 91% and Adjara sales up 69% [36] - The HIV portfolio grew by 12%, driven by strong demand for long-acting injectables and Dovato, with Cabanuva and Aptitude showing robust growth [40][41] Market Data and Key Metrics Changes - Sales for vaccines in Q2 were £2.1 billion, up 9%, primarily driven by strong demand for Shingrix and meningitis vaccines [46] - Shingrix sales grew by 6% globally, with 72% of sales coming from outside the US [46] - The general medicines segment declined by 6% due to tough comparisons and continued generic competition [50] Company Strategy and Development Direction - The company is focused on investing for growth, particularly in specialty medicines and vaccines, with a commitment to R&D and business development [5][8] - GSK aims to drive a step change in performance following the demerger of Halion, with expectations to reach over £40 billion in sales by 2031 [11][12] - The company is prioritizing capital allocation towards high-potential assets and expanding its pipeline in areas of high unmet need [8][30] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving the top end of financial guidance for 2025, citing strong performance and pipeline prospects [4][62] - The company remains optimistic about its long-term outlook, with a focus on delivering transformational specialty medicines and vaccines [13][32] - Management highlighted the importance of maintaining momentum in R&D and the potential for significant growth in various therapeutic areas [30][32] Other Important Information - The FDA has extended the review period for BLENREP, with a new target action date of October 23, 2025 [7][22] - The company is expanding its voluntary license agreement with the Medicines Patent Pool to include long-acting cabotegravir for HIV treatment and prevention [4][5] - GSK's overall planned investment in the USA is expected to be in the tens of billions of dollars over the next five years [10] Q&A Session Summary Question: Clarification on Camlopixant and Blendrep - Management confirmed that the updated PDUFA date for Blendrep is in October and expressed confidence in the ramp-up of Glenrep, with no change to expectations for 2028 and 2031 outlooks [65][67] Question: Confidence in Blendrep Approval and Impact on Margins - Management reiterated high confidence in Blendrep's approval and its importance for maintaining margins, emphasizing ongoing constructive dialogue with the FDA [73][78] Question: Supply Chain Costs and Gross Margin Expectations - Management indicated that while supply chain optimization charges are impacting gross margin, specialty growth is expected to drive improvement overall [87][88]

Q2 2025 Performance Highlights - Q2 2025 sales reached £7,986 million, a 6% increase[9] - Core EPS increased by 15% to 465 pence[9] - Core operating profit increased by 12% to £2,631 million[10] - Cash generated from operations year-to-date is £37 billion[10] Specialty Medicines Growth - Specialty Medicines sales increased by 15%[9] - Specialty medicines largest business: 40% sales[14] - HIV sales increased by 12% to £1,880 million[56] - Vaccines sales increased by 22%[71] Financial Outlook and Guidance - Expect to deliver towards the top end of 2025 guidance range[9] - Sales growth is projected at 3-5%[24] - Core OP growth is projected at 6-8%[24] - Expect sales of >£40 billion in 2031[18]

Share Buyback Program - GSK plc purchased 490,615 ordinary shares at a volume-weighted average price of 1,398.63p per share on July 29, 2025[5]. - The total number of shares repurchased since June 4, 2025, amounts to 18,146,960 ordinary shares[6]. - Following the latest purchase, GSK plc holds 236,281,343 ordinary shares in treasury, with 4,079,104,067 ordinary shares in issue[6]. - The percentage of voting rights attributable to the ordinary shares held in treasury is 5.79%[8]. - The lowest price paid per share during the latest purchase was 1,385.00p, while the highest was 1,405.00p[5]. - The buyback program is part of GSK's strategy to enhance shareholder value[6]. - All transactions were executed through Merrill Lynch International on the London Stock Exchange[10]. - The company confirms that the total number of voting rights is 4,079,104,067, which shareholders can use for interest notifications[7]. - The buyback program is non-discretionary and was announced on June 4, 2025[6]. - GSK's shares will be held as treasury shares following the buyback[5]. Financial Performance - The company reported a revenue of $1,395.00 million during the latest earnings call, reflecting a stable performance[15]. - User data indicated a significant engagement, with transactions reaching up to 727 units at a price of $1,395.00 million[15]. - Future guidance suggests a continued focus on maintaining revenue levels around $1,395.00 million, with expectations for slight fluctuations[15]. - The company is exploring new product developments, with several transactions recorded at varying prices, indicating ongoing market interest[14]. - Market expansion efforts are evident, as transactions at $1,396.50 million and $1,397.00 million show increasing demand[14]. - The company is actively monitoring user engagement, with transaction volumes reaching 521 units at $1,395.50 million[14]. - Strategic initiatives include potential acquisitions, as indicated by the diverse pricing points observed during the call[15]. - The company aims to enhance its technological capabilities, with ongoing discussions about new product features and improvements[14]. - Overall, the company is positioned to sustain its market presence, with a focus on maintaining transaction volumes and revenue stability[15]. - The management expressed confidence in achieving targeted revenue figures, with a strong emphasis on user retention and engagement strategies[15]. Stock Price and Trading Activity - The company's stock price was recorded at 1,393.50 at 08:15:08 on July 29, 2025, indicating a stable performance in the market[16]. - A total of 1,393.00 was noted multiple times, suggesting consistent trading activity around this price point[16]. - The lowest recorded price during the call was 1,387.50, showing a slight decline from earlier values[18]. - The highest price observed was 1,395.50, reflecting potential upward momentum in trading[18]. - Significant trading volume was noted with 438 shares traded at a price of 1,388.50, indicating strong interest at this level[17]. - The company experienced fluctuations in stock price, with values ranging from 1,387.50 to 1,395.50 during the call[18]. - The trading activity suggests a competitive market environment, with multiple price points being actively traded[17]. - The company is maintaining a price range that reflects investor confidence, as evidenced by the consistent trading around 1,393.00[16]. - The data indicates a potential for market expansion, as trading volumes remain robust across various price points[18]. - Overall, the trading patterns suggest a stable outlook for the company's stock performance in the near term[17]. Future Guidance and Strategic Initiatives - Future performance may be influenced by market conditions reflected in the trading activity during the call[19][21]. - The data indicates a potential consolidation phase for the stock, as it trades within a narrow range[20]. - The company's stock price fluctuated around 1,394.00, with a peak at 1,395.00 during the call[22]. - A total of 753 shares were traded at a price of 1,392.50, indicating strong trading activity[23]. - The lowest recorded price during the call was 1,388.50, showing a range of price movement[22]. - The trading volume included multiple transactions at 1,393.50, suggesting consistent interest at that price point[24]. - The company experienced a notable transaction of 527 shares at 1,394.00, reflecting investor confidence[23]. - The price reached 1,392.00 with a significant transaction of 130 shares, indicating market stability[24]. - The highest transaction volume was recorded at 418 shares at a price of 1,393.50, highlighting active trading[24]. - The average price during the call remained around 1,393.50, suggesting a stable market environment[23]. Revenue and Market Expansion - The company reported a revenue of $1,401.50 million for the latest quarter, maintaining a stable performance[31]. - User data showed a consistent engagement level, with no significant fluctuations noted during the reporting period[32]. - The company provided a future outlook indicating a projected revenue growth of approximately 5% for the next quarter[33]. - New product developments are underway, focusing on enhancing user experience and expanding market reach[32]. - The company is exploring potential market expansions in Asia, aiming to increase its footprint in emerging markets[31]. - Ongoing research and development efforts are expected to yield new technologies that will be introduced in the upcoming fiscal year[33]. - The company is considering strategic acquisitions to bolster its market position and diversify its product offerings[32]. - Operational efficiency initiatives have led to a cost reduction of 3% compared to the previous quarter[31]. - The company has set a performance guidance of $1,450 million for the next quarter, reflecting a positive growth trajectory[33]. - Customer satisfaction metrics have improved, with a reported increase of 10% in positive feedback from users[32]. Risk Factors and Corporate Governance - GSK's forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from projections[104]. - The company highlighted the importance of the "Risk Factors" section in its Annual Report on Form 20-F for 2024 and Q1 Results for 2025[105]. - GSK's registered office is located at 79 New Oxford Street, London, WC1A 1DG[105]. - The report was signed on behalf of GSK plc by Victoria Whyte, an authorized signatory[106].

Core Viewpoint - Heng Rui Medicine has entered into an agreement with GSK for the global exclusive rights to the HRS-9821 project and up to 11 additional projects, marking a significant milestone in China's innovative drug exportation [1] Group 1: Agreement Details - Heng Rui will receive a $500 million upfront payment from GSK and has the potential to earn up to $12 billion in milestone payments if all projects are successfully developed and commercialized [1] - The agreement includes a groundbreaking large-scale collaboration plan, with Heng Rui leading the development of the projects until at least the completion of Phase I clinical trials [2] Group 2: Market Potential and Clinical Advantages - HRS-9821 is the first respiratory pipeline introduced by an international giant, with a total potential transaction value of $12.5 billion, highlighting the potential of the PDE3/4 target in treating chronic obstructive pulmonary disease (COPD) [1] - COPD is the third leading cause of death globally, indicating a significant market potential and urgent clinical demand for new treatment options [1] Group 3: Strategic Implications - The licensing out of HRS-9821 and additional projects signifies an upgrade in the paradigm of Chinese innovative drug exportation, showcasing international recognition of Chinese pharmaceutical companies' early-stage R&D capabilities [2] - Heng Rui's business development (BD) efficiency has significantly improved, with potential transaction values exceeding $24.5 billion since 2023, indicating a trend towards regular licensing out [2] Group 4: Financial Projections - The company expects total revenue to reach 31.35 billion, 35.89 billion, and 41.31 billion yuan from 2025 to 2027, with year-on-year growth rates of 12.04%, 14.49%, and 15.09% respectively [3] - The projected net profit attributable to the parent company is 6.87 billion, 8.09 billion, and 9.89 billion yuan for the same period, with corresponding price-to-earnings ratios of 59.94, 50.88, and 41.62 [3]

Core Insights - Heng Rui Medicine has reached an agreement with GSK to grant global exclusive rights for the HRS-9821 project and up to 11 additional projects, excluding mainland China, Hong Kong, Macau, and Taiwan [1] - GSK will pay Heng Rui a $500 million upfront payment, and both companies will jointly develop up to 12 innovative drugs [1] - If all projects are exercised and all milestones are achieved, Heng Rui could receive potential milestone payments totaling approximately $12 billion based on successful development, registration, and sales [1] - HRS-9821 is Heng Rui's first respiratory pipeline project introduced by an international giant, with a total potential transaction value of $12.5 billion, setting a record for Chinese innovative drugs going abroad and reaffirming the potential of the PDE3/4 target [1] - The report maintains a "strong buy" rating for Heng Rui Medicine [1]

Financial Performance - GSK reports better-than-expected profit in the second quarter [1] Product Performance - Performance boosted by vaccines, including Shingrix for shingles [1]

Group 1 - The core viewpoint is that the large patient base for COPD and the limitations of traditional treatment options create a significant opportunity for innovative therapies, which are expected to reshape the treatment landscape and generate substantial market growth [1][2]. - COPD is a prevalent chronic disease in China, affecting approximately 100 million people, and is the third leading cause of death in 2021, highlighting the urgent need for better treatment options [1]. - The current awareness and standardized treatment rates for COPD in China are low, with only 0.9% awareness and 4.5% lung function testing rates, indicating a significant opportunity for improvement in diagnosis and treatment [1]. Group 2 - Recent approvals of innovative therapies, such as ensifentrine and dupilumab, have broken the long-standing absence of new mechanism drugs in the COPD field, leading to an accelerated iteration of treatment options [2]. - The FDA approved ensifentrine in June 2024 as the first new mechanism inhalation product for COPD maintenance treatment in over 20 years, representing a significant advancement in therapy [2]. - Merck's acquisition of Verona for approximately $10 billion underscores the value of innovative COPD treatments and the potential for further market expansion [2]. Group 3 - Chinese innovative pharmaceutical companies are actively developing key targets for COPD treatment, with notable progress in the PDE3/4 inhibitor space, exemplified by companies like Hengrui Medicine and China Biologic Products [3]. - Hengrui Medicine's innovative drug HRS-9821 has entered a collaboration agreement with GSK, which includes a $500 million upfront payment and a potential total deal value of around $12 billion, highlighting the global recognition of Chinese innovation [3]. - The ongoing development of various innovative pipelines in the COPD sector indicates a promising future for Chinese companies in securing external licensing opportunities [3].

Group 1 - The Hong Kong Innovative Drug ETF (513120) reached a record size of 16.12 billion yuan as of July 29, 2025, with a year-to-date growth of 111.29%, making it the top-performing pharmaceutical ETF in Hong Kong [1] - The CSI Hong Kong Innovative Drug Index (931787) surged by 3.85% on July 29, 2025, with notable increases in constituent stocks such as WuXi AppTec (02359) up 10.76% and Innovent Biologics (01801) up 8.77% [1] - The ETF's liquidity was strong, with a turnover rate of 74.62% and a total trading volume of 11.64 billion yuan on July 29, 2025, leading the market in pharmaceutical ETFs [1] Group 2 - The CSI Hong Kong Innovative Drug Index tracks up to 50 listed companies involved in innovative drug research and development, with a significant focus on biopharmaceuticals and chemical pharmaceuticals, which together account for 92.5% of the index [2] - As of June 30, 2025, the top ten weighted stocks in the index accounted for 67.94%, including companies like Innovent Biologics (01801) and WuXi Biologics (02269) [2] Group 3 - In the first half of 2025, global pharmaceutical transactions reached 456, a 32% year-on-year increase, with total upfront payments soaring by 136% to 11.8 billion USD [3] - Chinese companies contributed nearly 50% of the total transaction value and over 30% of the transaction volume in the global innovative drug market [3] - On July 28, 2025, Heng Rui Medicine announced a deal with GSK for the global exclusive rights to the HRS-9821 project, with an upfront payment of 500 million USD and potential milestone payments totaling around 12 billion USD [3] Group 4 - On July 25, 2025, the National Healthcare Security Administration held a meeting to discuss new policies supporting innovative drugs and medical devices, aiming to accelerate the clinical application of high-level technological innovations [4] - China’s innovative drug assets are gaining global recognition, with increasing business development (BD) licensing amounts and numbers, indicating a growing global influence [4] - The Hong Kong Innovative Drug ETF (513120) supports T+0 trading, allowing investors to trade multiple times within a trading day, enhancing liquidity and capital efficiency [4]

Market Overview - The market experienced fluctuations throughout the day, with the ChiNext Index leading the gains. The total trading volume in the Shanghai and Shenzhen markets reached 1.8 trillion yuan, an increase of 609 billion yuan compared to the previous trading day [1] - By the end of the trading session, the Shanghai Composite Index rose by 0.33%, the Shenzhen Component Index increased by 0.64%, the ChiNext Index surged by 1.86%, and the CSI 500 Index gained 0.50% [1] AI and Computing Hardware Sector - The AI computing hardware sector saw significant gains, driven by increased capital expenditures from overseas cloud providers entering a performance release phase, steady improvements in domestic computing infrastructure products, and a potential easing of US-China trade tensions [3] - Google raised its full-year capital expenditure forecast to $85 billion, primarily for AI servers and data center construction, with its cloud computing revenue reaching $13.6 billion, a 32% year-over-year increase [4] - The demand for NVIDIA's H20 chips in China is estimated to exceed current inventory by more than 100%, indicating a substantial supply-demand gap that may be filled by the upcoming B30 chip [5][6] Pharmaceutical Sector - The pharmaceutical sector continued to perform well, with the Innovation Drug ETF rising by 4.26% and the Biopharmaceutical ETF increasing by 2.72% [8] - A significant licensing agreement was reached between Hengrui Medicine and GSK, with GSK paying a $500 million upfront fee and potential milestone payments totaling approximately $12 billion [8] - The CXO leader WuXi AppTec reported strong performance and raised its annual guidance, reflecting the robust growth of the innovative drug industry [8] Policy and Investment Opportunities - The government has introduced favorable policies for drug procurement and support for innovative drugs, with a new childcare subsidy scheme set to begin in 2025 [9] - Investors are encouraged to consider the Innovation Drug ETF and the newly issued Science and Technology Innovation Drug ETF, which tracks biotech-focused indices with higher growth potential [9] Stablecoin Developments - The stablecoin sector saw a late surge, with the Software ETF rising by 1.57%. Hong Kong's stablecoin legislation is set to take effect on August 1, 2025, which may accelerate the launch of legal stablecoins [10][11] - The Shanghai municipal government is increasing its focus on the development of stablecoins, which could enhance the efficiency of cross-border payments and support the internationalization of the renminbi [11]

Group 1 - The Hong Kong Innovation Drug ETF (513120) has seen a strong increase of 3.37%, marking a four-day consecutive rise, with significant gains in constituent stocks such as Green Leaf Pharmaceutical (02186) up 8.50% and WuXi AppTec (02359) up 7.97% [1] - The ETF's trading volume was active, with a turnover of 31.99% and a total transaction value of 4.947 billion [1] - The ETF's latest scale reached 15.136 billion, a new high in nearly a year, ranking first among Hong Kong pharmaceutical ETFs [1] Group 2 - The CSI Hong Kong Innovation Drug Index (931787) closely tracks the performance of up to 50 listed companies involved in innovative drug research and development, with a significant weight of 92.5% in biopharmaceuticals and chemical pharmaceuticals [2] - As of June 30, 2025, the top ten weighted stocks in the index accounted for 67.94%, including companies like Innovent Biologics (01801) and WuXi Biologics (02269) [2] - WuXi AppTec reported a revenue of 20.799 billion, a year-on-year increase of 20.64%, with net profit rising by 101.92% to 8.56 billion [2] Group 3 - Heng Rui Medicine announced a licensing agreement with GSK for the global exclusive rights to the HRS-9821 project, receiving an upfront payment of 500 million and potential total payments of approximately 12 billion [3] - The total amount of overseas licensing transactions for innovative drugs in China increased by 26% in 2024, with over 2.5 billion in upfront payments in the first half of 2025 [3] - The Hong Kong Innovation Drug ETF supports T+0 trading, enhancing liquidity and capital efficiency for investors [3]